Journal
PHARMACOECONOMICS
Volume 33, Issue 7, Pages 629-641Publisher
ADIS INT LTD
DOI: 10.1007/s40273-015-0302-y
Keywords
-
Categories
Funding
- Global Surgery Group, Johnson and Johnson, Inc.
- Johnson and Johnson, Inc.
Ask authors/readers for more resources
Despite consistently supportive evidence of clinical effectiveness and economic advantages compared with currently available non-surgical obesity treatments, patient access to bariatric and metabolic surgery (BMS) is impeded. To address this gap and better understand the relationship between value and access, the objectives of this study were twofold: (i) identify the multidimensional barriers to adoption of BMS created by clinical guidelines, public policies, and health technology assessments; and, most importantly, (ii) develop recommendations for stakeholders to improve patient access to BMS. Updated public policies focused on treatment and clinical guidelines that reflect the demonstrated advantages of BMS, patient education on safety and effectiveness, updated reimbursement policies, and additional data on long-term BMS effectiveness are needed to improve patient access.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available